Michael Kazinski

Xantos AG is a functional biology and drug discovery company developing biopharmaceuticals in the areas of cancer and metabolic diseases. Its business model is to develop drug discovery pipelines based on the validated targets and leads generated by its proprietary through target identification and validation system and to form indication specific joint research and development collaborations with pharmaceutical and biotechnology companies. It also offers customers its proprietary technology and cDNA/siRNA screening tools for research service deals. The company is headquartered in Munich, Germany.

Xantos AG is a functional biology and drug discovery company developing biopharmaceuticals in the areas of cancer and metabolic diseases. Its business model is to develop drug discovery pipelines based on the validated targets and leads generated by its proprietary through target identification and validation system and to form indication specific joint research and development collaborations with pharmaceutical and biotechnology companies. It also offers customers its proprietary technology and cDNA/siRNA screening tools for research service deals. The company is headquartered in Munich, Germany.